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Abstract
Background/Aim: Perfluoroalkyl substances (PFASs) are chemical compounds used in consumer
products and are linked with increase in cholesterol, thyroid disease, and pregnancy-induced
hypertension. However, their association with lung function is not completely understood.
Methods: Cross sectional 2011-12 U.S. population data from the National Health and Nutrition
Examination Survey (NHANES) was used (N=1,450, aged 12 to 79 years, 52% men). Serum
concentration of four PFASs, perfluorononanoic acid (PFNA), perfluorooctanoic acid (PFOA),
perfluorooctane sulfonic acid (PFOS), and perfluorohexane sulfonic acid (PFHxS) were assessed
using mass spectrometry and were categorized into tertiles. Lung function was measured by
spirometry as forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and
the ratio of FVC/FEV1 (%). Sex stratified adjusted linear regression analysis was used to predict
lung function with PFASs tertiles.
Results: In men all four PFASs serum concentrations and lung function was higher, except
FVC/FEV1 (%) which was lower than women (p<.001 for all). In men, compared with low
tertiles, high exposure to PFOS, PFNA, predicted a significant decrease in FEV1 and FVC,
respectively, and PFOA, PFOS, and PFHxS predicted significant low FVC/FEV1 (%) in
unadjusted models. In women, compared with low tertiles, high exposure to all PFASs predicted
a significant decrease in FEV1, FVC and FVC/FEV1 (%) (except PFHxS in FVC), respectively,
in unadjusted models (p<.001). No association was seen in adjusted models in both men and
women.
Conclusion: High PFASs exposure has a consistent significant negative impact on female lung
function in unadjusted analysis and this association needs further exploration.
Keywords: Perfluoroalkyl Substances, PFAS, NHANES, Public Health, Lung Function
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The Association of Perfluoroalkyl Substance Exposure and Lung Function in the U.S.
Population
Chemical exposures are a relevant public health concern due to the vast amount of
chemicals in the environment to which the public is exposed, often with unknown side effects.
Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are a group of chemicals that can be
found in carpets, clothing, food packaging, firefighting foam, and non-stick cookware coatings
(Pérez et al., 2013; Kirk et al., 2018; Timmermann et al., 2017). These chemicals are widely used
in common consumer products due to their hydrophobic, to water repellant, and lipophobic,
insoluble in fat, natures (Pérez et al., 2013; Kirk et al., 2018). PFASs have a high chemical and
thermal stability (Qin et al., 2017) meaning that they are less likely to break down in normal dayto-day conditions. This stability allows industries to use PFASs in the many consumer products.
Once absorbed through inhalation, oral or dermal routes, PFASs have been found to accumulate
in multiple tissues in humans, including the lungs (Pérez et al., 2013). PFASs have also been
found to cause an increase in cholesterol, increase the risk of a thyroid disease, decreased fertility
and pregnancy-induced hypertension in humans (Agency for Toxic Substances and Disease
Registry [ATSDR], 2018a; ATSDR, 2018b).
The lungs are one of the main tissues that accumulate PFASs after exposure (Pérez et al.,
2013) and yet little research has been done regarding lung function and outcomes with PFAS
exposure. There has been scant research on the association between exposures to PFASs and
lung function in the human population; most of the research has been on animal populations. In a
study conducted by Timmermann et al. (2017), PFASs exposure and asthma in children were
found to have a lower vaccine antibody response to measles, mumps and rubella (MMR)
vaccination. Children with an increased serum concentration of PFAS had higher odds of history
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of asthma in unvaccinated children compared to those who were vaccinated. A study on the
exposure of PFASs and children found that there is an association between PFASs and impaired
lung function (Qin et al., 2017).
More research has been conducted on animals involving PFASs and lung functions.
Studies have found that PFASs negatively impact the development of mammals, resulting in
lower birth weight and neonatal mortality. Research has demonstrated that the neonatal mortality
in animals was caused by under-developed lungs and the failure of lung function (Ye et al.,
2012). Other outcomes associated with PFAS and lungs include an increase in the
immunoglobulin IgE, which is associated with allergy response (Qin et al., 2017; Timmermann
et al., 2017) and an increase in airway inflammation and altered airway function in animal
models (Qin et al., 2017). Given the limited amount of evidence found in the animal models
involving the negative impact of PFASs on lung function, it is important to explore if the same is
true in human population.
The burdens of lung function disease, such as chronic obstructive pulmonary disease
(COPD), and asthma, have become more prominent in the United States (U.S.) (Cukic, Lovre,
Dragisic, & Ustamujic, 2012). COPD is characterized by the limitation of airflow in the lungs
(Carey et al., 2007). COPD is more prevalent in males than females, mainly due to the smoking
rate in males being higher than in females (Carey et al., 2007; LoMauro & Aliverti, 2018).
However, females develop COPD earlier than males due to the smaller lung capacity, creating a
faster decline in lung function (LoMauro & Aliverti, 2018). Asthma is more prevalent among
females than males in the general population (Carey et al., 2007; LoMauro & Aliverti, 2018),
although the prevalence and severity changes with age (Carey et al., 2007). Likewise, in
children, asthma incidence is more frequent in males (LoMauro & Aliverti, 2018).
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Statement of Purpose
The objective of this project is to determine what types of association PFASs exposure
have with lung function among the U.S. population. Using the National Health and Nutrition
Examination Survey (NHANES) 2011 to 2012, we hypothesized that increasing serum levels of
PFASs, specifically perfluorononanoic acid (PFNA), perfluorooctanoic acid (PFOA),
perfluorooctane sulfonic acid (PFOS), and perfluorohexane sulfonic acid (PFHxS), in the U.S.
population would be associated with decreased lung function, as assessed by spirometry, and will
differ by gender.
Literature Review
Perfluoroalkyl and Polyfluoroalkyl Substances
PFASs are a group of chemicals that consist of hundreds of different types, but only
about twelve are commonly found and studied (Rodriguez-Jorquera & Toor, 2015; ATSDR,
2018b). PFASs are chemicals that have a high thermal and chemical stability (Qin et al., 2017).
PFASs are made up of a carbon backbone, which can vary from a length of four carbons to
twelve carbons, with fluorine substitutions (ATSDR, 2018c) (see Figure 1). These carbonfluorine bonds provide strength giving the thermal and chemical stability that allows the
chemicals to be resistant to break down (Pérez et al., 2013). PFASs have a ‘head’ and a ‘tail’
(Figure 1). The ‘head’ and ‘tail’ can vary based on which PFAS chemical is being examined, due
to different molecular structures which affects the charge of the ‘head’. In a review published by
Kirk and colleagues (2018), the ‘head’ of the PFAS molecule was found to regulate where in the
body that the PFAS would accumulate.

PFAS EXPOSURE AND LUNG FUNCTION

8

Figure 1. PFNA molecule structure. Made using MolView (Bergwerf, 2015).
PFASs also have a hydrophobic and lipophobic nature (Pérez et al., 2013; Kirk et al.,
2018). Hydrophobic is a term used when referring to substances that are able to repel water, and
lipophobic is a term used when referring to substances that are not soluble in lipids or non-polar
solvents, such as fats. Due to these properties, PFASs are widely used in manufacturing products.
PFASs bind to serum proteins with high affinity. PFASs especially bind to albumin,
which acts as a transporter of insoluble molecules, because of the high affinity between the
receptor and its ligand (Kirk et al., 2018). PFASs bioaccumulate in the body, meaning that they
become concentrated inside the body due to the fact that the rate at which the body absorbs
PFASs is faster than what the body can excrete or catabolize. Perfluoroalkyl substances are
excreted mostly through the renal system (ATSDR, 2018b; Pérez et al., 2013). A study by Pérez
et al. (2013), found that PFASs have the highest accumulation in lung tissues. Liver and brain
tissue were also found to accumulate PFASs.
Exposures to PFASs
There are many ways that humans can be exposed to PFAS. Some of the products that
contain PFASs include food packaging, firefighting foam, non-stick cookware, photographic
films and furniture (Pérez et al., 2013; Kirk et al., 2018; Timmermann et al., 2017). There are
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three exposure routes into the body; the oral route into the body is the most rapid and the most
common form of exposure for the general population. The dermal route is possible but less
likely; however, it could be an exposure route for those occupational workers who handle
products with PFAS (Rodriguez-Jorquera & Toor, 2015; ATSDR, 2018b). The inhalation route
has not been studied enough in epidemiological studies, but is considered the most common form
of exposure route for the occupational workers (Rodriguez-Jorquera & Toor, 2015; ATSDR,
2018b).
PFAS exposure could also occur through contaminated water, soil, air, and food. The
industries that manufacture products release PFASs into the surrounding air or the surface water
around the industrial plant (ATSDR, 2018b; ATSDR, 2018c). Manufacturing of some PFAS
products in the U.S. has been phased out since the early 2000’s (ATSDR, 2018c). PFAS still
remain present in the environment due to their resistance to break down. Thus, they seep into the
ground-water, and they persist in the soil. Wind and rain are able to carry the chemicals great
distances, spreading the exposure radius to places where there are no manufacturing plants
(ATSDR, 2018a; ATSDR, 2018b).
Health Effects
Several health effects have been associated with PFAS exposures. The main health
effects associated with humans are increased cholesterol, an increased risk of thyroid disease and
a decrease in female fertility (ATSDR, 2018a; ATSDR, 2018b). Pregnant woman are also
affected by PFAS exposure; they have an increased chance of high blood pressure, pre-eclampsia
and lower birth weight in infants (ASTDR, 2018a).
Animal studies have been conducted to help determine the health effects caused by
PFASs exposure. Some of the main health effects found in animal studies have been liver
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damage, immune toxicity, and cancer of the liver, pancreas and reproductive organs (ASTDR,
2018b; Rodriguez-Jorquera & Toor, 2015). Animal studies on PFASs have also been found to
impact birth outcomes, such as delayed development, increased birth defects, reduced birth
weight and a reduced number of live births (ATSDR, 2018a; Rodriguez-Jorquera & Toor, 2015).
Respiratory health effects. Few studies have been conducted on the respiratory effects
of PFASs on humans. There are, however, a few studies that demonstrate that PFASs have some
impact on the respiratory system. In a study conducted by Timmermann et al. (2017), PFASs
exposure and asthma in children were found to have a lower vaccine antibody response to the
MMR vaccination. Children with an increased serum concentration of PFAS had higher odds of
history of asthma in unvaccinated children compared to those who were vaccinated. Another
study conducted by Qin et al. (2017) found an association between PFAS exposure and impaired
lung function in children. The lungs are one of the main tissues in which PFASs accumulate
(Pérez et al., 2013).
More studies have been done on animals to test the respiratory effects caused by PFASs.
In a study by Ye et al. (2012), PFAS exposure caused neonatal mortality in mice, which was
caused by under-developed lungs. Animals exposed to PFAS have also been found to increase
serum immunoglobulin E (Qin et al., 2017; Timmermann et al., 2017). In a study conducted with
mice pups, exposure to PFAS were found to cause altered airway function, induced airway
inflammation and increased the airway response in an allergic murine model (Qin et al., 2017).
Spirometry
Spirometry is a pulmonary function test, also known as a breathing test, which is able to
analyze overall lung function (Sood, Dawson, Henkle, Hopkins-Price, & Quails, 2007).
Spirometry is used in testing and surveillance for lung diseases, such as asthma, COPD, chronic
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bronchitis, emphysema and pulmonary fibrosis (Sood et al., 2007; Coates et al., 2013). The test
is conducted by measuring the volume of air exhaled by the patient. The volume can either be
calculated directly, when the patient has exhaled into an expandable chamber, or by measuring
the air flow and then calculating the volume from the air flow (Coates et al., 2013). Spirometry
tests are conducted multiple times in one sitting to ensure consistent results. The common
spirometry measurements include forced vital capacity (FVC), forced expiratory volume (FEV)
and forced vital capacity divided by forced expiratory volume (FEV/FVC).
FVC is the largest amount of air that a patient is able to forcibly exhale after breathing in
as deep as they can, it is done to calculate the magnitude of restricted breathing (Coates et al.,
2013; Hankinson et al., 2010). The lower the FVC the greater the breathing restriction. Forced
expiratory volume in one second (FEV1) is used to calculate how much air a patient can force
from their lungs in one second (Coates et al., 2013; Hankinson et al., 2010). FEV1 calculations
help determine the severity of breathing problems; see Table 1. A ratio of FEV1 to FVC is
calculated to determine if the results are normal when compared to reference values (Coates et
al., 2013). Reference values set for each of these variables based on NHANES III, see Table 1
(Sood et al., 2007; Hankinson et al., 2010).
Table 1
NHANES III Reference Values of Spirometry (FEV1 and FEV1/FVC)
Degree of Severity
Normal
Mild
Moderate
Moderately Severe
Severe
Very Severe

FEV1 % Predicted
~100
>70
60-69
50-59
35-49
<35

FEV1/FVC Ratio
.70-.80
<.70
<.70
<.70
<.70
<.70
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Methods
Data Source and Study Sample
This was a cross sectional study using existing data from NHANES 2011 to 2012 from
healthy individuals (N = 1,450; 12 years through 79 years old; 752 men and 698 women) to
evaluate the association between PFASs and lung function measured by spirometry (FEV1, FVC,
and FEV1/FVC). NHANES is a population-based survey conducted on individuals within the
U.S. population in assigned subgroups focusing on specific diseases and risk factors. The total
number of individuals who were interviewed in the 2011 to 2012 NHANES was 9,756 and 9,338
of those individuals were examined (Centers for Disease Control and Prevention, National
Center for Health Statistics [CDC NCHS], 2018). These participants are examined in a mobile
examination center (MEC).
The MEC is used to ensure a standardized examination environment for laboratory
measurements, physical assessments and examinations. Questionnaires were also used to collect
demographic and personal information (age, sex, race/ethnicity, income, education, and
occupation), medical history (current health status and chronic conditions), physical activity,
alcohol and tobacco use or exposure, and reproductive history. Physical examination included
measurement of height and weight. The MEC is able to collect biological specimens such as,
blood, urine, vaginal swabs and oral rinse. All of the MEC laboratory staff complete training to
learn the standardized NHANES laboratory protocols. All survey materials, consent documents
and examination information for the NHANES 2011 to 2012 dataset are publicly available on the
NHANES website as part of the Centers for Disease Control and Prevention (CDC NCHS, 2018;
CDC NCHS, 2015a; CDC NCHS, 2015b).
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PFASs Concentration
PFASs chemicals, also known as polyfluoroalkyl chemicals (lately PFCs) in NHANES
2011 to 2012 dataset, were extracted in the blood samples taken in the MEC. The serum from the
blood samples, a minimum of 0.5mL, is collected and are refrigerated within four hours of
collection. To test the serum, online solid phase extraction-high performance liquid
chromatography-turbo ion spray-tandem mass spectrometry (online SPE-HPLC-TIS-MS/MS)
was used to quantitatively detect PFOA, PFOS, PFNA and PFHxS (CDC NCHS, 2013). The
serum samples are prepared with 0.1M of formic acid, after being thawed and then inserted in the
automated SPE-HPLC-TIS-MS/MS. The mass spectrometer is calibrated every three to six
months and the instrument sensitivity is checked before each test of samples (CDC NCHS,
2013). The lower limit of detection (LLOD) of each PFAS substance is stated as: PFOA (0.10
ng/mL), PFOS (0.20 ng/mL), PFNA (0.08 ng/mL), and PFHxS (0.10 ng/mL) (CDC NCHS,
2014a). If a sample had results below the lower limit of detection the NHANES study designers
placed an imputed value in the database. This value is calculated by taking the LLOD divided by
square root of two (LLOD/√2), which can be calculated for each PFAS substance; PFOA (0.07
ng/mL), PFOS (0.14 ng/mL), PFNA (0.06 ng/mL), and PFHxS (0.07 ng/mL) (CDC NCHS,
2014a; CDC NCHS, 2013).
Spirometry Measurement
The spirometry measurements were done with the individuals in the MEC. The MEC
used the Ohio 822/827 dry-rolling seal volume spirometer. Before each test was performed using
the spirometer, a calibration syringe was used to calibrate the spirometer. Before each test, the
individuals were asked a series of safety questions (see Appendix A), and if the questions were
answered positively (“Yes”, “Refused”, or “Don’t Know”) then the individual did not perform a
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spirometry test (CDC NCHS, 2011). The spirometry was performed by having the individuals
stand up, unless physically incapable, extend their neck and elevate their chin. A nose clip was
placed on the nose to prevent any air leaks (CDC NCHS, 2014b). The NHANES examiner had
the individual take the deepest breath possible so that the lungs would fill with the maximum
amount of air, and then blow the air out as fast and forcibly as possible. When exhaling into the
mouthpiece of the spirometer, the individual made sure as to keep their lips around it to create a
tight seal (CDC NCHS, 2014b). FVC, the maximum volume of air exhaled forcefully after a
maximal inspiration, was calculated. In an adult (11 to 79 years old), the forced exhalation has a
minimum of six seconds of exhalation and in children (six to ten years old), the forced exhalation
has a minimum of three seconds of exhalation (CDC NCHS, 2014b; CDC NCHS, 2011). FEV1,
the volume of air exhaled during the first second, was calculated (CDC NCHS, 2011).
Statistical Analysis
Analyses were performed using the Statistical Package for the Social Science (SPSS)
(IBM SPSS Statistics for Mac, Version 25.0. Armonk, NY: IBM Corp., 2017). All tests were two
sided and conducted at the α = .05 level of significance. Analysis was presented for the overall
data set and also by gender. Descriptive statistics computed for continuous variables included
measures of centrality (mean, median) and dispersion (standard deviation, range) (age, PFNA,
PFOA, PFOS, PFHxS, FEV1, FVC and FEV1/FVC). Frequency distributions (number and
percentage) were examined for categorical variables (race/ethnicity and annual household
income). Race/ethnicity was recoded from five values into three values: non-Hispanic White
(reference), non-Hispanic Black, and all others. Annual household income was recoded from
fourteen values into three values: <$25,000 (reference), $25,000 to <$55,000, and $55,000+ (see
Appendix B).
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Chi-square test was used to determine the statistical significance between the categorical
variables across gender. The statistical significance of associations between the continuous
variables across gender was tested by an independent-sample t-test for normally distributed
variables (age, FEV1, FVC, and FEV1/FVC) or by a Mann-Whitney U test for non-normally
distributed continuous variables (PFNA, PFOA, PFOS, and PFHxS).
As PFASs were not normally distributed, each individual PFAS was categorized into
tertiles. Four individual PFASs (exposures/predictor) were tested in each of the lung function test
(outcome/dependent) analyses (FVC, FEV1, and FEV1/FVC).
Linear regression analysis was performed to assess association between each PFAS tertile
separately as predictor (PFNA, PFOA, PFOS, and PFHxS) and the outcome variable (FEV1,
FVC, or FEV1/FVC). First unadjusted linear models were analyzed, followed by age adjusted
linear regression and then multivariable regression for other covariates including age, annual
household income, race/ethnicity. A total of 12 unadjusted linear regressions, 12 age-adjusted
linear regressions, and 12 multivariable linear regressions were analyzed. Categorical variables
with more than two levels were dummy coded including, PFAS tertiles, annual household
income, and ethnicity. Analysis was repeated using continuous log transformed PFASs variables.
Results
Descriptive Statistics
As seen in Table 2, the overall sample of 1,450 NHANES participants, 51.9% were male.
The mean age of individuals was 39.26 ± 18.85 years. A higher proportion of this group had
annual household income ≥$55,000. Compared to non-Hispanic White and non-Hispanic Black,
other races constituted the prevalent group at 39% overall and when comparing males versus
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females (Table 2). No significant differences between gender was found for age, annual
household income, and race/ethnicity.
Table 2
Characteristics of 2011-2012 NHANES Participants, Overall and by Gender: Male and Female
Characteristic Variable
Overall N= 1450
(51.9%)
(48.1%)
p-value*
39.26 (18.85)
39.42 (18.96)
39.09 (18.75)
.737
Age (years), mean (SD)
.644
Annual Household Income, n
<$25,000
427 (29.4)
214 (28.5)
213 (30.5)
$25,000-$54,999
443 (30.6)
230 (30.6)
213 (30.5)
≥$55,000
580 (40.0)
308 (41.0)
272 (39.0)
Race/Ethnicity, n (%)
.865
497 (34.3)
253 (33.6)
244 (35.0)
NonHispanic White
NonHispanic Black
386 (26.6)
203 (27.0)
183 (26.2)
All Other
567 (39.1)
296 (39.4)
271 (38.8)
PFNA (ug/L), median (IQR)
.89 (.74)
.98 (.78)
.81 (.64)
<.001†
PFOA (ug/L), median (IQR)
2.05 (1.47)
2.33 (1.40)
1.73 (1.34)
<.001†
PFOS (ug/L), median (IQR)
6.33 (6.68)
7.96 (7.27)
4.99 (5.27)
<.001†
.91 (.98)
<.001†
PFHxS (ug/L), median (IQR)
1.22 (1.41)
1.64 (1.60)
2628.77 (611.33)
<.001
FEV1 (mL), mean (SD)
3101.09 (880.0)
3539.49 (864.59)
FVC (mL), mean (SD)
3868.86 (1058.77) 4475.55 (968.90)
3215.23 (702.84)
<.001
<.001
FEV1/FVC (%), mean (SD)
80.34 (8.71)
78.98 (8.91)
81.81 (8.25)
*p-values were found by using the chi-square test for categorical variables and a t-test for continuous variables.
†p-values were found by using the mann-whitney U test for non normal distribution of the continuous variables.
p-value reports differences between the two categories: Male and Female.

Male participants had a higher exposure to all four PFASs (0.98, 2.33, 7.96, 1.64 vs 0.81,
1.73, 4.99, 0.91; all p < .001) respectively, compared to females. Males also had higher
spirometry measures of FEV1 (3539.49 vs 2628.77; p < .001) and FVC (4475.55 vs 3215.23; p <
.001) compared to females. However, the reverse was seen in the ratio of FEV1/FVC in which
female had the highest spirometry measure (81.81 vs 78.98; p = <.001) compared to males,
respectively. In this sample the overall PFNA value was higher than the national value (CDC
DHHS, 2019) reported from NHANES 2011 to 2012 (.89 vs .88), as well as PFOS (6.33 vs
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6.31). The overall PFOA value was lower than the national value (2.05 vs 2.08) as well as
PFHxS (1.22 vs 1.28).
Linear Regression Analysis
In linear regression analysis (Table 3), when compared with low PFOS tertiles, in men,
high exposure showed a significant decrease in FEV1 in unadjusted models. In unadjusted
models, with PFNA high exposure showed a negative association with FEV1 (trend towards
significance, p = .062). In women, all four PFAS’s high exposure tertiles predicted a decrease in
FEV1 in the unadjusted models (Table 3), additionally the same effect was seen for PFNA for
medium exposure. However, in neither men nor women, there was no such negative association
between PFASs and FEV1 seen in age or multivariable adjusted models. In men, almost all
PFASs in general, except PFNA, showed a significant increase in FEV1 in medium and high
tertiles, compared to the low tertile, both in the age adjusted and multivariable adjusted models.
No such association was seen in unadjusted models in men. In the rest of our descriptions of our
results, only the negative associations of all four PFASs with lung function are presented.

PFAS EXPOSURE AND LUNG FUNCTION

18

Table 3
Association of PFASs Serum Concentration with FEV1 in NHANES 2011-2012 Participants
using Unadjusted and Multivariable Adjusted Linear Regression
FEV1
Male
B (95% CI)
PFOA
Unadjusted
Age-adjusted
Multivariable-adjusted
PFOS
Unadjusted
Age-adjusted
Multivariable-adjusted
PFNA
Unadjusted
Age-adjusted
Multivariable-adjusted
PFHxS
Unadjusted

Med 67.23 (-84.25, 218.71)
High 35.66 (-116.28, 187.60)
Med 108.07 (-24.20, 240.33)
High 212.49 (78.02, 346.96)
Med 83.76 (-41.76, 209.28)
High 181.30 (52.71, 309.89)
Med
High
Med
High
Med
High

135.53 (-13.34, 284.39)
-190.78 (-341.75, -39.80)
314.04 (181.67, 446.40)
207.85 (65.93, 349.77)
284.00 (158.51, 409.49)
212.04 (76.79, 347.29)

Med 35.12 (-115.83, 186.08)
High -144.09 (-295.20, 7.01)
Med 90.63 (-42.39, 223.65)
High 9.35 (-125.15, 143.85)
Med 104.73 (-21.35, 230.81)
High 62.12 (-66.04, 190.28)

p-value

Female
B (95% CI)

p-value

.384
.645
.109
.002
.191
.006

-33.40 (-144.15, 77.34)
-149.69 (-260.56, -38.82)
47.15 (-41.65, 135.96)
86.30 (-5.26, 177.85)
-15.82 (-98.61, 66.97)
18.19 (-67.62, 104.00)

.554
.008
.298
.065
.708
.677

.074
.013
<.001
.004
<.001
.002

-76.68 (-184.96, 21.60)
-333.91 (-442.31, -225.52)
13.74 (-75.44, 102.92)
2.96 (-92.73, 98.64)
-30.50 (-113.36, 52.36)
-4.11 (-92.75, 84.53)

.165
<.001
.762
.952
.470
.927

.648
.062
.181
.891
.103
.342

-117.68 (-227.24, -8.12)
-241.86 (-351.54, -132.18)
-28.41 (-117.18, 60.36)
-56.03 (-146.41, 34.36)
-22.48 (-104.46, 59.51)
-32.51 (-116.63, 51.62)

.035
<.001
.530
.224
.591
.448

Med 75.61 (-75.85, 227.07)
.327
-39.68 (-150.09, 70.72)
-186.67 (-296.83, -76.51)
High 52.96 (-98.66, 204.57)
.493
.019
34.14 (-54.81, 123.09)
Age-adjusted
Med 159.04 (26.43, 291.65)
.004
11.18 (-79.45, 101.82)
High 196.41 (62.83, 329.99)
Multivariable-adjusted
Med 122.44 (-3.91, 248.80)
.058
-8.59 (-91.24, 74.07)
.028
-62.04 (-146.87, 22.80
High 144.57 (15.52, 273.61)
*In all models, the reference category was the respective low PFAS tertile. Med = Medium
Variables that were adjusted for: age, annual household income and race/ethnicity.
N = 1450

.481
.001
.451
.809
.838
.152

As shown in Table 4, women, when compared with the low tertiles, high exposure in both
PFOS and PFNA and medium exposure of PFNA showed a significant decrease in FVC in
unadjusted models. In women, PFNA high exposure predicted a decrease in FVC in the age-
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adjusted model, showing a trend towards significance (p = 0.104). However, in women, no such
association was seen in multivariable adjusted models for any of the four PFASs. In men, only
PFNA high exposure showed a significant decrease in FVC in unadjusted models.
Table 4
Association of PFASs Serum Concentration with FVC in NHANES 2011-2012 Participants using
Unadjusted and Multivariable Adjusted Linear Regression
FVC
Male
B (95% CI)
PFOA
Unadjusted
Age-adjusted
Multivariable-adjusted
PFOS
Unadjusted
Age-adjusted
Multivariable-adjusted
PFNA
Unadjusted
Age-adjusted
Multivariable-adjusted
PFHxS
Unadjusted

p-value

Female
B (95% CI)

p-value

Med 50.63 (-118.96, 220.22)
High 129.61 (-40.49, 299.71)
Med 79.71 (-81.67, 241.10)
High 255.53 (91.46, 419.61)
Med 51.21 (-97.94, 200.36)
High 193.17 (40.37, 345.97)

.558
.135
.333
.002
.500
.013

-14.45 (-142.25, 113.36)
-95.03 (-222.98, 32.91)
48.28 (-69.05, 165.60)
88.72 (-32.24, 209.68)
-49.55 (-154.49, 55.39)
-10.99 (-119.76, 97.79)

.824
.145
.419
.150
.354
.843

Med 232.91 (65.64, 400.18)
High -76.71 (-246.35, 92.93)
Med 359.78 (197.95, 521.61)
High 206.60 (33.09, 380.11)
Med 307.67 (158.25, 457.09)
High 180.47 (19.43, 341.51)

.006
.375
<.001
.020
<.001
.028

-53.90 (-179.44, 71.65)
-315.71 (-441.39, -190.03)
13.01 (-104.55, 130.57)
-66.48 (-192.61, 59.65)
-59.66 (-164.61, 45.29)
-74.78 (-187.05, 37.49)

.400
<.001
.828
.301
.265
.191

.861
.045
.784
.410
.604
.916

-134.43 (-260.81, -8.05)
-239.92 (-366.44, -113.39)
-66.60 (-183.65, 50.45)
-98.73 (-217.91, 20.46)
-56.75 (-160.64, 47.13)
-50.87 (-157.47, 55.73)

.037
<.001
.264
.104
.284
.349

Med
High
Med
High
Med
High

-15.14 (-184.43, 154.15)
-173.39 (-342.86, -3.93)
22.65 (-139.76, 185.07)
-65.92 (-233.14, 95.30)
39.60 (-110.35, 189.56)
8.17 (-144.26, 160.60)

.066
30.63 (-96.90, 158.16)
Med 158.84 (-10.26, 327.94)
High 214.11 (44.84, 383,37)
.013
115.80 (-243.05, 11.45)
Age-adjusted
Med 218.58 (57.40, 379.76)
.008
88.06 (-29.20, 205.32)
<.001
38.12 (-81.37, 157.61)
High 316.83 (154.47, 479.20)
Multivariable-adjusted
Med 146.73 (-3.14, 296.59)
.055
16.40 (-88.31, 121.10)
High 205.46 (52.41, 358.51)
.009
-79.87 (-187.33, 27.59)
*In all models, the reference category was the respective low PFAS tertile. Med = Medium
Variables that were adjusted for: age, annual household income and race/ethnicity.
N = 1450

.637
.074
.141
.531
.759
.145
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When compared with low PFOA, PFOS, and PFHxS tertiles, in men, high exposure
showed a decrease in FEV1/FVC in unadjusted models (Table 5) with PFOA trending towards
significance (p = .086). For women, all four PFASs, in high exposure tertiles predicted decrease
in FEV1/FVC for unadjusted models, as well as medium exposure of PFHxS. Also in women,
medium PFHxS exposure showed a decrease in FEV1/FVC in the age-adjusted model, trending
towards significance (p = .053). However, in neither men nor women, was any such association
seen in multivariable adjusted models. Results did not change in analysis using continuous log
transformed PFASs variables.
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Table 5
Association of PFASs Serum Concentration with FEV1/FVC in NHANES 2011-2012
Participants using Unadjusted and Multivariable Adjusted Linear Regression
FEV1/FVC
Male
B (95% CI)
p-value
PFOA
Unadjusted
Age-adjusted
Multivariable-adjusted
PFOS
Unadjusted
Age-adjusted
Multivariable-adjusted
PFNA
Unadjusted
Age-adjusted
Multivariable-adjusted
PFHxS
Unadjusted

Female
B (95% CI)

p-value

Med
High
Med
High
Med
High

0.62 (-0.93, 2.18)
-1.37 (-2.93, 0.19)
1.05 (-0.29, 2.40)
0.50 (-0.87, 1.87)
0.98 (-0.34, 2.30)
0.87 (-0.48, 2.22)

.431
.086
.125
.478
.145
.207

-0.74 (-2.22, 0.75)
-2.90 (-4.38, -1.41)
0.23 (-1.02, 1.49)
-0.06 (-1.35, 1.24)
0.70 (-0.52, 1.93)
0.29 (-0.98, 1.56)

.331
<.001
.716
.929
.260
.658

Med
High
Med
High
Med
High

-1.22 (-2.76, 0.31)
-3.05 (-4.61, -1.49)
0.66 (-0.70, 2.01)
1.15 (-0.31, 2.60)
0.87 (-0.46, 2.20)
1.71 (0.28, 3.15)

.118
<.001
.344
.123
.198
.019

-1.08 (-2.57, 0.41)
-2.89 (-4.38, -1.40)
0.10 (-1.16, 1.35)
1.50 (0.16, 2.85)
0.55 (-0.68, 1.77)
1.49 (0.18, 2.80)

.154
<.001
.877
.029
.381
.026

Med
High
Med
High
Med
High

1.23 (-0.33, 2.78)
-0.04 (-1.60, 1.52)
1.84 (.50, 3.18)
1.66 (0.30, 3.02)
1.85 (0.54, 3.17)
1.50 (0.16, 2.84)

.123
.958
.007
.017
.006
.028

-0.56 (-2.05, 0.93)
-1.77 (-3.26, -0.28)
0.57 (-0.68, 1.82)
0.58 (-0.70, 1.86)
0.51 (-0.70, 1.72)
0.10 (-1.14, 1.35)

.463
.020
.372
.372
.409
.871

Med
-1.06 (-2.61, 0.50)
.182
-2.13 (-3.61, -0.65)
High -2.42 (-3.97, -0.86)
.002
-3.31 (-4.79, -1.83)
Age-adjusted
Med
-0.19 (-1.54, 1.17)
.788
-1.24 (-2.49, 0.02)
High -0.92 (-2.28, 0.44)
.185
-0.91 (-2.19, 0.37)
Multivariable-adjusted
Med
0.25 (-1.08, 1.58)
.708
-0.77 (-2.00, 0.45)
High -1.22 (-1.48, 1.24)
.860
-0.24 (-1.50, 1.02)
*In all models, the reference category was the respective low PFAS tertile. Med = Medium
Variables that were adjusted for: age, annual household income and race/ethnicity.
N = 1450

.005
<.001
.053
.162
.216
.706
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Discussion
Overall, we observed a consistent statistically significant negative association between
lung function and high PFAS exposure in females and some association in males in the
unadjusted models. We did not observe an association that was consistently significant in the
age-adjusted and multivariable adjusted models.
One of the possible explanations of the above results could be that PFASs are endocrine
disruptors (ED) and ED can impact males and females differently. Several published studies
report gender dependent differences for PFASs related impacts, for example in a study by Byrne
et al. (2018), a positive association between PFNA and PFOS with free T3 (triiodothyronine) was
noted in females, conversely a negative association was seen with male free T3. In a separate
study (Jain & Ducatman, 2019), PFNA and PFOA were positively associated with low-density
lipoprotein cholesterol (LDL) and total cholesterol in obese males, however PFNA and PFDA
(perfluorodecanoic acid) were positively associated with LDL and total cholesterol in obese
females.
The different associations between PFASs and lung function across genders noted in this
study could be due to the differences in male and female lung function. The dissimilarities in
lung structure and function between males and females start at the lung development prenatal
phase (Carey et al., 2007; LoMauro & Aliverti, 2018). Female lungs mature sooner than males in
the prenatal phase (Carey et al., 2007; LoMauro & Aliverti, 2018) and at birth, females have
smaller lungs with fewer respiratory bronchioles (LoMauro & Aliverti, 2018). Males have bigger
lungs than females after puberty meaning that males have a larger total number of alveoli thus
they have a larger alveolar surface area (Carey et al., 2007; LoMauro & Aliverti, 2018). Male’s
lung shapes are pyramidal whereas females have a more prismatic lung shape (LoMauro &
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Aliverti, 2018) and recoil pressure of lungs differ due to the size of the lungs and the maximum
descending forces.
Other evidence also supports different impact of PFASs on male and female lung
function. Qin et al. (2017) reported an association between PFAS exposure and impaired lung
function in only male children. Although they believed that their sample size for females was too
small, resulting in a significant association only for males (Qin et al., 2017). Sex hormones may
impact the gender specific relationship between PFASs and lung function. Zhou et al. (2017)
reported that in asthmatic children, PFASs had a negative association with testosterone levels
and a positive association with estradiol levels.
Relatively more studies are available on animals that tested the respiratory effects caused
by PFASs. In a study by Ye et al. (2012), PFAS exposure was linked with neonatal mortality in
mice, which was caused by under-developed lungs. In a separate study of mice pups, exposure to
PFAS altered airway function, induced airway inflammation and increased the airway response
(Qin et al., 2017).
Our study was internally valid, because we addressed chance, confounding, and bias.
Chance is not an explanation of our findings; our results consistently showed negative
associations between different PFASs and FEV1, FVC, and FEV1/FVC in unadjusted models of
females. For example, the B-value and 95% confidence interval (CI) of PFOA, showed a
negative association in the unadjusted models for FEV1, -149.69 (-260.56, -38.82), p = .008.
This negative association showed up consistently across the female lung function outcomes such
as PFOA in unadjusted models with FEV1/FVC, and PFOS with FVC. Besides a valid
association between PFASs exposure and lung function, other possible explanations for this
finding could include bias and residual confounding. We adjusted for many known confounders,

PFAS EXPOSURE AND LUNG FUNCTION

24

except smoking. This was due to the complexity of methods utilized to collect smoking data in
NHANES 2011 to 2012. However, there could still be unmeasured confounders that bias the
observed association. One of those unmeasured confounders could be genetic/biological factors
that cannot be measured quantitatively.
As this was a cross sectional study, based on data from a national survey, selection bias
was minimized by utilizing random sampling. To reduce information bias, the data collection
team was provided extensive training to reduce errors in data collection, interviews, and data
entry. Our study was externally valid and can be applied to the general U.S. population; both
genders and different ethnicities, and a wide range of socio-economic strata, were taken into
account.
According to the well-defined Hill’s epidemiology criteria of causality (Crislip, 2010)
exposure should precede outcome could not be met as NHANES is a cross sectional study. This
study did have a dose response relationship between the exposure (PFASs: high compared to
low) and the lung function. For almost all PFASs, in unadjusted models in females high exposure
vs. low exposure was associated with poorer lung function. But among those PFASs that had
significantly strong negative association with lung function, even the medium tertile of exposure
in unadjusted models showed significant decrement in lung performance. This association was
noted for PFNA in with FEV1, PFNA with FVC and PFHxS with FEV1/FVC ratio. Another
causality criteria is consistency; we had consistent results for female lung function across all
three types of spirometry measures in the unadjusted models; high exposure of PFNA was found
to be significant in all three spirometry measures, high exposure in PFHxS was found to be
significant in two spirometry measures (FEV1 & FEV1/FVC). Our study also had biological
plausibility, as it known that PFASs exposure increases airway inflammation (Qin et al., 2017).
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Strengths/Limitations
One of the strengths of this study is that we used nationally representative data from a
large, well known cross sectional study (NHANES). Some limitations of the study are not
accounting for smoking as a confounder.
Conclusion
PFASs exposure was associated with decreased lung function in females in unadjusted
models among a diverse population of participants from the NHANES 2011 to 2012 data. PFASs
exposure is a public health concern due to its wide spread use in consumer products and health
implications. More research is needed to explore association between PFASs exposure and lung
function because the lungs are one of the main tissues where PFAS accumulate (Pérez et al.,
2013).
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Appendix A: NHANES Spirometry Exclusion Questions
•

SPQ.010

Does SP [the participant] have a painful ear infection?

•

SPQ.020

Have you ever had eye surgery? (Do not include cosmetic surgery on the

eyelid or skin around the eye.)
•

SPQ.030

Was the eye surgery in the last 3 months?

•

SPQ.040

Have you ever had open chest or abdominal surgery?

•

SPQ.050

Was the open chest or abdominal surgery in the last 3 months?

•

SPQ.060

Did you or anyone in your household have tuberculosis in the past year?

•

SPQ.070a

Has a doctor or other health professional told you that you had an

aneurysm?
•

SPQ.070b

Has a doctor or other health professional told you that you had a collapsed

lung?
•

SPQ.070c

Has a doctor or other health professional told you that you had a detached

retina?
•

SPQ.070d

Has a doctor or other health professional told you that you had a stroke?

•

SPQ.070e

Has a doctor or other health professional told you that you had a heart

attack?
•

SPQ.080

Did this stroke happen in the last 3 months?

•

SPQ.090

Was your heart attack in the last 3 months?

•

SPQ.100

In the past month, have you coughed up blood?

PFAS EXPOSURE AND LUNG FUNCTION

31

Appendix B: NHANES Variable Names Table
NHANES
Variable Name

Variable

Description

LBXPFOA

Serum PFAS Level

Perfluorooctanoic Acid (PFOA)

LBXPFOS

Serum PFAS Level

Perfluorooctane Sulfonic Acid (PFOS)

LBXPFNA

Serum PFAS Level

Perfluorononanoic Acid (PFNA)

LBXPFHS

Serum PFAS Level

Perfluorohexane Sulfonic Acid (PFHxS)

RIAGENDR

Gender

Gender of participant (Female or Male)

RIDAGEYR

Age

Age of participant in years

RIDRETH1

Race/Hispanic Origin

Reported Race/Hispanic Origin of participants

RaceEth3Groups

Race/Hispanic Origin

Recode of RIDRETH1 into three groups of
Race/Hispanic origin

INDHHIN2

Income

Annual Household Income

Income3lvl

Income

Recode of INDHHIN2 into three groups of income

SPXNFEV1

FEV1 Test

Baseline FEV 1 (mL)

SPXNFVC

FVC Test

Baseline FVC (mL)

FEV1_FVC

FEV1/FVC

Computed variable taking FEV1 diving that by FVC
and multiplying it by 100 for a %

Note: NHANES=National Health and Nutrition Examination Survey, PFAS=Perfluoroalkyl
Substance
Source: Centers for Disease Control and Prevention, National Center for Health Statistics (CDC
NCHS), 2018.
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Appendix D: List of Competencies Met in Integrative Learning Experience
CEPH Foundational Competencies
Evidence-based Approaches to Public Health
2. Select quantitative and qualitative data collection methods appropriate for a given public health context
3. Analyze quantitative and qualitative data using biostatistics, informatics, computer-based programming and
software, as appropriate
4. Interpret results of data analysis for public health research, policy or practice
Communication
19. Communicate audience-appropriate public health content, both in writing and through oral presentation

WSU MPH Population Health Concentration Competencies
3. Demonstrate the ability to contextualize and integrate knowledge of specific population health issues.
4. Address diversity when evaluating population health issues related to improving population health, reducing
disparities, or increasing equity.
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